Nā huahana
-
High Purity Peptides Retatrutide 10mg no ke kaumaha a me ka maʻi diabetes
Maʻemaʻe: >99%
Mokuʻāina: Lyophilized Powder
Na hiʻohiʻona: ka pauka keʻokeʻo
Hōʻike: 5mg/10mg/15mg/20mg/30mg
-
Retatrutide
ʻO Retaglutide kahi dipeptidyl peptidase-4 (DPP-4) inhibitor class hypoglycemic lāʻau lapaʻau hou e hiki ke pale i ka hōʻino ʻana o ka glucagon-like peptide-1 (GLP-1) a me ka glucose-dependent insulin-releasing polypeptide (GIP) e DPP-4 enzyme i loko o ka ʻōpū a me ke koko, e hoʻolōʻihi i kā lākou hana, me ka ʻole o ka hoʻoulu ʻana i ka insulin basalβ i ka pae. e hoʻemi ana i ka huna ʻana o ka glucagon e nā pūnaewele α pancreatic, a laila ʻoi aku ka maikaʻi o ka mālama ʻana i ke kō koko postprandial. Hana maikaʻi ʻo ia ma ke ʻano o ka hopena hypoglycemic, hoʻomanawanui, a me ka hoʻokō.
-
ʻO ka sodium Inclisiran
ʻO Inclisiran sodium API (Active Pharmaceutical Ingredient) ke aʻo nui ʻia ma ke kahua o ka RNA interference (RNAi) a me nā therapeutics cardiovascular. Ma ke ʻano he siRNA pālua ʻelua e kuhikuhi ana i ka ʻano PCSK9, hoʻohana ʻia ia i ka noiʻi preclinical a me ka noiʻi lapaʻau e loiloi i nā hoʻolālā hoʻopaʻa ʻana i nā gene-silencing lōʻihi no ka hoʻohaʻahaʻa ʻana i ka LDL-C (low-density lipoprotein cholesterol). He mea hoʻohālike ia no ka noiʻi ʻana i nā ʻōnaehana lawe siRNA, kūpaʻa, a me nā therapeutics RNA i hoʻopaʻa ʻia i ka ate.
-
Fmoc-Gly-Gly-OH
ʻO Fmoc-Gly-Gly-OH kahi dipeptide i hoʻohana ʻia ma ke ʻano he papa kūkulu hale ma ka solid-phase peptide synthesis (SPPS). Loaʻa iā ia nā koena glycine ʻelua a me kahi Fmoc-protected N-terminus, e ʻae ana i ka elongation chain peptide controlled. Ma muli o ka liʻiliʻi a me ka maʻalahi o ka glycine, ua aʻo pinepine ʻia kēia dipeptide i ka pōʻaiapili o ka peptide backbone dynamics, linker design, a me ka hoʻohālikelike ʻana i nā peptides a me nā protein.
-
Fmoc-Thr(tBu)-Phe-OH
ʻO Fmoc-Thr(tBu)-Phe-OH kahi poloka hale dipeptide i hoʻohana mau ʻia i loko o ka solid-phase peptide synthesis (SPPS). Mālama ka pūʻulu Fmoc (9-fluorenylmethyloxycarbonyl) i ka N-terminus, aʻo ka hui tBu (tert-butyl) e pale i ke kaulahao ʻaoʻao hydroxyl o threonine. Hoʻopaʻa ʻia kēia dipeptide pale no kāna kuleana i ka hoʻomaʻamaʻa ʻana i ka elongation peptide kūpono, e hōʻemi ana i ka racemization, a me ka hoʻohālikelike ʻana i nā kumu kikoʻī kikoʻī i ka hoʻolālā protein a me nā haʻawina pili.
-
AEEA-AEEA
ʻO AEEA-AEEA he hydrophilic, maʻalahi spacer i hoʻohana mau ʻia i ka peptide a me ka noiʻi conjugation lāʻau. Aia i loko o ʻelua mau ʻāpana ethylene glycol, pono ia no ke aʻo ʻana i nā hopena o ka lōʻihi o ka loulou a me ka maʻalahi i ka pilina molekala, solubility, a me ka hana olaola. Hoʻohana pinepine ka poʻe noiʻi i nā ʻāpana AEEA e loiloi i ka hopena o nā spacers i ka hana o nā antibody-drug conjugates (ADCs), peptide-drug conjugates, a me nā bioconjugates ʻē aʻe.
-
![Fmoc-L-Lys[Eic(OtBu)-γ-Glu(OtBu)-AEEA]-OH](https://cdn.globalso.com/gentolexgroup/Glepaglutide10-300x300.png)
Fmoc-L-Lys[Eic(OtBu)-γ-Glu(OtBu)-AEEA]-OH
ʻO kēia pūhui he lysine derivative i hoʻohana ʻia i ka peptide synthesis a me ka hoʻomohala ʻana i ka lāʻau conjugate. Hōʻike ia i kahi pūʻulu Fmoc no ka pale N-terminal, a me kahi hoʻololi ʻaoʻao-chain me Eic(OtBu) (eicosanoic acid derivative), γ-glutamic acid (γ-Glu), a me AEEA (aminoethoxyethoxyacetate). Hoʻolālā ʻia kēia mau ʻāpana e aʻo i nā hopena lipidation, spacer chemistry, a me ka hoʻokuʻu ʻana i ka lāʻau. Ua noiʻi nui ʻia ma ka pōʻaiapili o nā hoʻolālā prodrug, nā mea hoʻopili ADC, a me nā peptides pili membrane.
-
![Fmoc-L-Lys[Ste(OtBu)-γ-Glu-(OtBu)-AEEA-AEEA]-OH](https://cdn.globalso.com/gentolexgroup/Glepaglutide9-300x300.png)
Fmoc-L-Lys[Ste(OtBu)-γ-Glu-(OtBu)-AEEA-AEEA]-OH
ʻO kēia pūhui he lysine derivative i hoʻololi ʻia i hoʻohana ʻia i ka peptide synthesis, ʻoi loa no ke kūkulu ʻana i nā conjugates peptide i manaʻo ʻia a multifunctional. Hiki i ka pūʻulu Fmoc ke hana stepwise ma o Fmoc solid-phase peptide synthesis (SPPS). Hoʻololi ʻia ke kaulahao ʻaoʻao me ka stearic acid derivative (Ste), γ-glutamic acid (γ-Glu), a me ʻelua AEEA (aminoethoxyethoxyacetate) linkers, e hāʻawi ana i ka hydrophobicity, nā waiwai uku, a me ka spacing maʻalahi. Hoʻomaʻamaʻa maʻamau ia no kāna kuleana i nā ʻōnaehana hoʻopuka lāʻau, me ka antibody-drug conjugates (ADCs) a me nā peptides e komo ana i ke kelepona.
-
ʻO Liraglutide Anti-Diabetics no ka mālama ʻana i ke kō koko CAS NO.204656-20-2
Mea hoʻoikaika kino:Liraglutide (analog o ke kanaka glucagon-like peptide-1 (GLP-1) i hana ʻia e ka hū ma o ka ʻenehana recombination genetic).
Inoa Kimia:Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Nā mea ʻē aʻe:Disodium Hydrogen Phosphate Dihydrate, Propylene Glycol, Hydrochloric Acid a/a i ʻole Sodium Hydroxide (e like me nā mea hoʻoponopono pH wale nō), Phenol, a me ka wai no ka hoʻokomo ʻana.
-
Hoʻoponopono ʻo Leuprorelin Acetate i ka huna ʻana o nā Hormones Gonadal
Ka inoa: Leuprorelin
Helu CAS: 53714-56-0
Kumu molekala: C59H84N16O12
Kaumaha molekula: 1209.4
Helu EINECS: 633-395-9
Ka hoʻololi kikoʻī: D25 -31.7° (c = 1 i ka 1% acetic acid)
Māmā: 1.44±0.1 g/cm3 (Wanamua)
-
Boc-His(Trt)-Aib-Gln(Trt)-Gly-OH
Boc-His(Trt)-Aib-Gln(Trt)-Gly-OHhe tetrapeptide i pale ʻia i hoʻohana ʻia i ka synthesis peptide a me nā haʻawina hoʻolālā. Mālama ka pūʻulu Boc (tert-butyloxycarbonyl) i ka N-terminus, aʻo nā hui Trt (trityl) e pale i nā kaulahao ʻaoʻao o ka histidine a me ka glutamine e pale i nā hopena makemake ʻole. ʻO ka heleʻana o Aib (α-aminoisobutyric acid) e hoʻoikaika i nā conformations helical a hoʻonui i ka paʻa o ka peptide. He waiwai kēia peptide no ka noiʻi ʻana i ka hoʻopili ʻana i ka peptide, kūpaʻa, a ma ke ʻano he scaffold no ka hoʻolālā ʻana i nā peptides hana biologically.
-
BPC-157
Hoʻohana ka BPC-157 API i ke kaʻina hana solid phase synthesis (SPPS):
Maʻemaʻe kiʻekiʻe: ≥99% (ʻike HPLC)
Ke koena haumia haʻahaʻa, ʻaʻohe endotoxin, ʻaʻohe haumia metala kaumaha
Paʻa paʻa, hoʻihoʻi ikaika, kākoʻo i ka hoʻohana pae injection
E kākoʻo i ka lako o ka pae gram a me kilokani e hoʻokō i nā pono o nā pae like ʻole mai R&D a hiki i ka ʻoihana.